NYBC Ventures is one of the first venture funds focused solely on blood and cell therapy—covering benign hematology, transfusion medicine, and infectious disease—rather than general biotech, and it is backed by New York Blood Center, a nonprofit community blood center, giving portfolio companies direct access to its researchers, cell-manufacturing capacity, source materials, and transfusion expertise. The fund also backs infrastructure technologies like cell-separation and robotic blood-draw systems alongside therapeutics, and it uses non-exclusive, non-financial collaborations, such as with CSL, to help identify and validate promising science for larger biopharma partners.